{"title":"Pharmacokinetics in the calf of a long-acting chloramphenicol formulation administered intravenously and intramuscularly.","authors":"E Bousquet","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In a preliminary study, 3 different chloramphenicol doses were tested by intramuscular (im) route, the highest one (90 mg/kg) being selected, based upon the duration of therapeutic serum levels (41.7 h). Following intravenous (iv) administration at this dose rate, the main pharmacokinetic parameters were: half-life of 6.0 h; body clearance, 0.101 l.kg-1.h-1; steady-state volume of distribution, 0.864 l.kg-1. Following a single im administration at the same dose, a mean maximum serum concentration of 22.9 microgram.ml-1 (Cmax) was reached in a mean time of 8.9 h (Tmax), therapeutic serum levels were achieved in an average period of 41.3 h. The mean half-life of the terminal phase was 10.3 h. Absolute bioavailability calculated based on 3 calves was 70.9 +/- 23.3% by im route. Pharmacokinetics of the long-acting formulation were confirmed in a repeated-dose study using the dosage schedule selected (2 injections im of 90 mg/kg at a 48 h interval).</p>","PeriodicalId":7914,"journal":{"name":"Annales de recherches veterinaires. Annals of veterinary research","volume":"21 Suppl 1 ","pages":"47S-55S"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de recherches veterinaires. Annals of veterinary research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In a preliminary study, 3 different chloramphenicol doses were tested by intramuscular (im) route, the highest one (90 mg/kg) being selected, based upon the duration of therapeutic serum levels (41.7 h). Following intravenous (iv) administration at this dose rate, the main pharmacokinetic parameters were: half-life of 6.0 h; body clearance, 0.101 l.kg-1.h-1; steady-state volume of distribution, 0.864 l.kg-1. Following a single im administration at the same dose, a mean maximum serum concentration of 22.9 microgram.ml-1 (Cmax) was reached in a mean time of 8.9 h (Tmax), therapeutic serum levels were achieved in an average period of 41.3 h. The mean half-life of the terminal phase was 10.3 h. Absolute bioavailability calculated based on 3 calves was 70.9 +/- 23.3% by im route. Pharmacokinetics of the long-acting formulation were confirmed in a repeated-dose study using the dosage schedule selected (2 injections im of 90 mg/kg at a 48 h interval).